Bergom Translational Research Laboratory
The overarching research goal of the Bergom laboratory is to identify novel molecular targets to improve and personalize breast cancer care. The Bergom laboratory embraces collaborative research and also prioritizes the education and training of students and post-doctoral fellows.
We have a research program focusing on defined targets – the DiRas family of tumor suppressors – and the role of these proteins in cancer development, promotion, and progression. We also have a research program using next generation sequencing and novel genetic tools to identify targets that will allow tailored radiation therapy and other treatments in breast cancer, specifically focusing on the role of the tumor microenvironment in breast cancer treatment responses. The goals of these studies are to identify predictive and prognostic features of breast cancer to better classify and treat breast cancers, and ultimately to identify new treatment strategies to improve patient outcomes.Learn More
Main Arms of the Bergom Laboratory
(Currey A, Patten CR, Bergom C, Wilson JF, Kong AL.) Breast J. 2018 Nov;24(6):902-910.
(Flister MJ, Bergom C.) Trends Cancer. 2018 Jun;4(6):429-444.
(Bergom C, Currey A, Desai N, Tai A, Strauss JB.) Front Oncol. 2018;8:87.
(Jagtap J, Sharma G, Parchur AK, Gogineni V, Bergom C, White S, Flister MJ, Joshi A.) Biomed Opt Express. 2018 Feb 01;9(2):543-556.
(Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT.) Clin Cancer Res. 2018 Apr 15;24(8):1917-1931.
(Kimmick GG, Li X, Fleming ST, Sabatino SA, Wilson JF, Lipscomb J, Cress R, Bergom C, Anderson RT, Wu XC, Written on behalf of the Center for Disease Control and Prevention National Program of Cancer Registry Patterns of Care Study Group.) J Geriatr Oncol. 2018 May;9(3):214-220.
Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.
(Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY.) Int J Radiat Oncol Biol Phys. 2018 Jun 01;101(2):274-284.
(Gonyo P, Bergom C, Brandt AC, Tsaih SW, Sun Y, Bigley TM, Lorimer EL, Terhune SS, Rui H, Flister MJ, Long RM, Williams CL.) Oncogene. 2017 12 14;36(50):6873-6883.
(Flister MJ, Tsaih SW, Stoddard A, Plasterer C, Jagtap J, Parchur AK, Sharma G, Prisco AR, Lemke A, Murphy D, Al-Gizawiy M, Straza M, Ran S, Geurts AM, Dwinell MR, Greene AS, Bergom C, LaViolette PS, Joshi A.) Breast Cancer Res Treat. 2017 Aug;165(1):53-64.
(Fish BL, Gao F, Narayanan J, Bergom C, Jacobs ER, Cohen EP, Moulder JE, Orschell CM, Medhora M.) Health Phys. 2016 11;111(5):410-9.
(Bergom C, Kelly T, Bedi M, Saeed H, Prior P, Rein LE, Szabo A, Wilson JF, Currey AD, White J.) Int J Radiat Oncol Biol Phys. 2016 09 01;96(1):65-71.
(Bergom C, Hauser AD, Rymaszewski A, Gonyo P, Prokop JW, Jennings BC, Lawton AJ, Frei A, Lorimer EL, Aguilera-Barrantes I, Mackinnon AC Jr, Noon K, Fierke CA, Williams CL.) J Biol Chem. 2016 May 13;291(20):10948.
Carmen Bergom, MD, PhD
Department of Radiation Oncology
8701 Watertown Plank Rd.
Milwaukee, WI 53226